Role of NLRC5 in progression and reversal of hepatic fibrosis
详细信息 查看全文
- 作者：Xuejiao Liua ; b ; liuxuejiao0615@163.com" class="auth_mail" title="E-mail the corresponding author ; Yuting Wua ; b ; Yang Yanga ; b ; Wanxia Lia ; b ; Cheng Huanga ; b ; Xiaoming Menga ; b ; Jun Lia ; b ; c ; lj@ahmu.edu.cn" class="auth_mail" title="E-mail the corresponding author
- 关键词：NLRC5 ; Hepatic fibrosis ; HSCs reversion ; Reversal of hepatic fibrosis
- 刊名：Toxicology and Applied Pharmacology
- 出版年：2016
- 出版时间：1 March 2016
- 年：2016
- 卷：294
- 期：Complete
- 页码：43-53
- 全文大小：1778 K
文摘
- •
The activated HSCs can be reverted to quiescent HSCs by MDI treatment.
- •
NLRC5 expressed differentially during different stages of hepatic fibrosis and its reversal.
- •
Enforced NLRC5 in reverted LX-c cells boosted the expression of α-SMA and Col1α1.
- •
Blockade of NLRC5 diminished α-SMA and Col1α1 expression.
- •
NLRC5 might provide a novel therapeutic approach for liver fibrosis.